CA3061893A1 - Selenium containing pharmaceutical agents, compositions, and methods relating thereto - Google Patents
Selenium containing pharmaceutical agents, compositions, and methods relating thereto Download PDFInfo
- Publication number
- CA3061893A1 CA3061893A1 CA3061893A CA3061893A CA3061893A1 CA 3061893 A1 CA3061893 A1 CA 3061893A1 CA 3061893 A CA3061893 A CA 3061893A CA 3061893 A CA3061893 A CA 3061893A CA 3061893 A1 CA3061893 A1 CA 3061893A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- insulin
- glucose
- cells
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| US62/508,730 | 2017-05-19 | ||
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3061893A1 true CA3061893A1 (en) | 2018-11-22 |
Family
ID=64274560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3061893A Pending CA3061893A1 (en) | 2017-05-19 | 2018-05-01 | Selenium containing pharmaceutical agents, compositions, and methods relating thereto |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (enExample) |
| EP (1) | EP3624809A4 (enExample) |
| JP (1) | JP7224303B2 (enExample) |
| CN (2) | CN120647702A (enExample) |
| AU (1) | AU2018269403B2 (enExample) |
| CA (1) | CA3061893A1 (enExample) |
| RU (1) | RU2765286C2 (enExample) |
| SA (1) | SA519410561B1 (enExample) |
| SG (1) | SG11201909932YA (enExample) |
| WO (1) | WO2018212980A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002305073A1 (en) * | 2001-03-22 | 2002-10-08 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| US7488720B2 (en) * | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| EP2192905A4 (en) | 2007-08-29 | 2010-11-10 | Adam Lubin | METHOD FOR SELECTIVE THERAPY OF DISEASE |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| CN105377271A (zh) | 2013-03-15 | 2016-03-02 | 全技术公司 | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 |
| MX2016011897A (es) * | 2014-03-14 | 2017-04-27 | Alltech Inc | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
-
2018
- 2018-05-01 CN CN202510741418.6A patent/CN120647702A/zh active Pending
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/ja active Active
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 AU AU2018269403A patent/AU2018269403B2/en active Active
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/zh active Pending
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en not_active Ceased
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/ru active
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/ar unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2765286C2 (ru) | 2022-01-28 |
| NZ758538A (en) | 2025-08-29 |
| JP7224303B2 (ja) | 2023-02-17 |
| WO2018212980A1 (en) | 2018-11-22 |
| CN110545822A (zh) | 2019-12-06 |
| EP3624809A1 (en) | 2020-03-25 |
| US11613552B2 (en) | 2023-03-28 |
| BR112019022918A2 (pt) | 2020-05-26 |
| CN120647702A (zh) | 2025-09-16 |
| RU2019134865A (ru) | 2021-06-21 |
| RU2019134865A3 (enExample) | 2021-06-30 |
| AU2018269403B2 (en) | 2025-03-27 |
| EP3624809A4 (en) | 2021-03-03 |
| US11014954B2 (en) | 2021-05-25 |
| JP2020520904A (ja) | 2020-07-16 |
| SA519410561B1 (ar) | 2024-03-06 |
| US20210238216A1 (en) | 2021-08-05 |
| US20200123191A1 (en) | 2020-04-23 |
| AU2018269403A1 (en) | 2019-11-14 |
| SG11201909932YA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016222315B2 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| US20220267780A1 (en) | Conjugates of bile acids and their derivatives for active molecules delivery | |
| US20140179779A1 (en) | Deuterium Substituted Fumarate Derivatives | |
| EP2954780A1 (en) | Methods of modulation of branched chain acids and uses thereof | |
| JP2022501331A (ja) | 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法 | |
| WO2004050122A1 (ja) | 高血糖症に起因する疾患の予防又は治療剤 | |
| US11613552B2 (en) | Pharmaceutical agents, compositions, and methods relating thereto | |
| EP4615462A1 (en) | Methods and compositions for treating wolfram syndrome | |
| HK40017181A (en) | Pharmaceutical agents, compositions, and methods relating thereto | |
| CN110799518B (zh) | 钴胺素衍生物及其用于治疗因缺乏维生素b12供应引起的疾病的用途 | |
| BR112019022918B1 (pt) | Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos | |
| US20050119197A1 (en) | Naadp analogues for modulating t-cell activity | |
| EP4487698A1 (en) | A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human | |
| EP3144001B1 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| EP4616853A1 (en) | Lipo-hydroxamic acid derivative and pharmaceutical use thereof | |
| US20230346765A1 (en) | Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof | |
| US20190040014A1 (en) | Solid Forms of an S-Nitrosoglutathione Reductase Inhibitor | |
| HK1235284B (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| HK1235284A1 (en) | Compositions of selenoorganic compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250312 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250313 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250714 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250905 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251111 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251111 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260424 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260729 |